Compare Abeona Therapeutics Inc (ABEO) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Yum! Brands, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while Yum! Brands, Inc. trades at $149.01 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 93.8× Abeona Therapeutics Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | YUM | |
|---|---|---|
Market Cap | $421.19M | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $168.16 |
52-Week Low | $4.17 | $138.21 |
Enterprise Value | $276.10M | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
YUM Brands trades at $148.91, up 2.46% with recent earnings beats offset by food safety concerns. Technical indicators show bearish momentum with support at $141, while fundamentals reveal strong revenue growth to $8.21B in 2025 and net income of $1.56B. The company recently completed the $1.2B sale of Pizza Hut China, streamlining operations amid cyclospora outbreak impacts on Taco Bell sales.
YUM presents a mixed outlook with 37% analyst buy ratings and $174.60 price target suggesting 17% upside, but faces near-term headwinds from food safety investigations and consumer sentiment. Long-term growth depends on KFC/Taco Bell execution and digital strategy success amid elevated debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
